The University of Colorado completes exclusive option agreement to commercialise eyesight medical device to medtech Galaxy Ophthalmics.

The University of Colorado has exported rights to commercialise an implantable medical device to tackle the effects of glaucoma to local medtech firm Galaxy Ophthalmics.

Glaucoma is the second leading cause of irreversible blindness on the planet, with over 60 million sufferers worldwide. It is a group of eye diseases that attack the optic nerve which can currently be tackled with surgeries which drain the eye’s inner fluid, and return a 50% failure rate after five years.

Colorado’s innovation allows…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?